Woodlands, TX-based Repros Therapeutics Inc.RPRX is a development-stage biopharmaceutical company focused on the development of treatments for hormonal and reproductive system disorders. The company currently has two candidates in its pipeline: enclomiphene (previously known as Androxal) and Proellex. Enclomiphene is Repros' lead pipeline candidate that is under FDA review for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function.
Repros' second pipeline candidate, Proellex, is currently in a phase II development for the treatment of uterine fibroids and endometriosis.
With no approved product in the company's portfolio at the moment and enclomiphene being its lead pipeline candidate, investor focus will remain on regulatory updates regarding enclomiphene.
Overall, the company has posted an average positive earnings surprise of 17.95%.
Currently, Repros has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Repros reported a loss of 27 cents per share in the third quarter of 2015, a penny narrower than the consensus estimate of a loss of 28 cents.
Revenues: Third-quarter revenues (which consisted entirely of interest income) decreased 50% from the year-ago quarter to $1,000.
Key Stats: Late last month, Repros received a huge setback when the FDA cancelled an advisory panel meeting with the Division of Bone, Reproductive and Urologic Products that was scheduled for Nov 3 for enclomiphene. The FDA informed that certain concerns cropped up late in the review related to the bio-analytical method validation that could affect interpretability of certain pivotal study data. A final response from the FDA is expected by Nov 30.
Check back later for our full write up on this RPRX earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
REPROS THERAPEU (RPRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
